The most significantly enriched mutations, however, were amplifications of PIK3CA (2.9% vs <0.01%) and fibroblast growth factor (FGF)-associated genes including FGF4 (5% vs 0.7%), FGF3 (5.2% vs 0.8%), CCND1 (5.2% vs 0.8%), FGF19 (4.7% vs 0.8%), and FGFR1 (3.8% vs 0.2%), some of which (PIK3CA, FGFR1) had current clinical trials in NSCLC (Supplementary Table S2). Here, FGF4 is linked to non-small cell lung carcinoma.